Clinical Study
Atorvastatin Treatment Does Not Alter Pulse Wave Velocity in Healthy Adults
Table 1
Baseline characteristics of study participants by drug assignment.
| | | Atorvastatin
() | Placebo
() | value |
| | Age, y | 52.6 ± 15.7 | 58.7 ± 8.1 | 0.08 | | Men, (%) | 9 (43%) | 16 (55%) | 0.39 | | Height, cm | 170.7 ± 11.4 | 171.8 ± 8.8 | 0.69 | | Weight, kg | 80.9 ± 18.4 | 78.3 ± 17.0 | 0.62 | | BMI, kg/m2 | 27.3 ± 4.0 | 26.4 ± 4.4 | 0.47 | | HR, bpm | 67 ± 9 | 69 ± 11 | 0.49 | | SBP, mmHg | 119.2 ± 13.7 | 115.4 ± 12.2 | 0.30 | | DBP, mmHg | 75.5 ± 8.9 | 72.6 ± 7.8 | 0.23 | | TC, mmol/L | 5.24 ± 1.26 | 5.36 ± 0.86 | 0.70 | | LDL-C, mmol/L | 3.05 ± 1.17 | 3.27 ± 0.75 | 0.43 | | HDL-C, mmol/L | 1.58 ± 0.54 | 1.62 ± 0.47 | 0.76 | | TG, mmol/L | 1.34 ± 0.73 | 1.13 ± 0.47 | 0.22 | | CK, U/L | 157.1 ± 110.4 | 120.8 ± 77.8 | 0.14 | | Activity counts, counts/da | 169.6 ± 160.8 | 166.5 ± 115.0 | 0.94 | | Moderate activity, min/d | 103.7 ± 51.8 | 112.9 ± 50.0 | 0.58 | | Vigorous activity, min/d | 6.5 ± 13.8 | 5.2 ± 9.6 | 0.74 |
|
|
Data are means ± SD or proportions. BMI, body mass index; C, cholesterol; CK, creatine kinase; DBP, diastolic blood pressure; HR, resting heart rate; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SBP, systolic blood pressure; TG, triglycerides.
aIn thousands.
|
